Virus Like Particles (VLPs) such the HBsAg-s capsid protein of HBV are self assembling non infectious particles useful not only as vaccines but also as delivery templates for putative protective epitopes for chimeric vaccine purposes. The HBsAg VLP is particulate and has been demonstrated to stimulate both B and T cell responses. Whilst the very successful current use of the HBsAg VLP as the safe and effective vaccine against HBV infection, the VLP is generally delivered with an alum adjuvant although the molecule has the capacity to act as an intrinsic adjuvant for foreign surface expressed epitopes. This latter capacity may overcome some of the limitations associated the restricted number of adjuvants licenced for human use. The generation of chimeric recombinant VLPs from a variety of viral sources offers an exciting option for vaccine development, although there are procedural challenges that need to be overcome to enable the technology to be translated to high production yields of satisfactory specificity and purity. This paper describes by way of illustration the amenability of VLP technology for vaccine production in a pilot study that developed a chimeric recombinant HBsAg VLP that surface expressed peptide sequences from the carboxyl terminus of the catalase gene of the gastric pathogen Helicobacter pylori. The study revealed that the chimeric VLP expressed both humoral and CMI mediated responses to both HBV and H. pylori and also suggested a degree of protection was generated against bacterial challenge in a murine challenge model. However, the work also highlighted some of the significant remaining challenges with the use of this technology which are further explored in this paper.